Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indoco Remedies Gains USFDA Final Approval for Allopurinol Tablets USP 200 mg
Details : Zyloprim-Generic (allopurinol) is a xanthine oxidase inhibitor. It is indicated for the treatment of primary or secondary gout, leukemia, lymphoma and solid tumor malignancies.
Product Name : Zyloprim-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2025
Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : ZonMw | University Medical Center Groningen | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Radboud University Medical Center, Nijmegen | ACE Pharmaceuticals BV
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2020
Lead Product(s) : Allopurinol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : ZonMw | University Medical Center Groningen | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Radboud University Medical Center, Nijmegen | ACE Pharmaceuticals BV
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : South-Eastern Norway Regional Health Authority | University of Oslo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lowering Uric Acid in Live Kidney Donors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2017
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : South-Eastern Norway Regional Health Authority | University of Oslo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Technische Universität Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundación para la Investigación del Hospital Clínico de Valencia | Universidade do Porto | Oslo University Hospital | Università degli Studi di Udine
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2017
Lead Product(s) : Allopurinol
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Technische Universität Dresden | UMC Utrecht | KU Leuven | University of Zurich | University of Vienna | Fundación para la Investigación del Hospital Clínico de Valencia | Universidade do Porto | Oslo University Hospital | Università degli Studi di Udine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
IVIVR Assessing PK Parameters Used to Establish Bioequivalence
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2015
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2012
Lead Product(s) : Allopurinol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2011
Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2011
Lead Product(s) : Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
